RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 3

Registered title, quoted from ClinicalTrials.gov

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

An open trial on lymphoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 31 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 31

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteAffiliated Cancer Hospital of Xinjiang Medical University新疆医科大学附属肿瘤医院UrumqiHospital page
  2. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  3. Study siteFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page
  4. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  5. Study siteFirst Affiliated Hospital of Henan University of Science and Technology河南科技大学第一附属医院LuoyangHospital page
  6. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  7. Study siteFirst Affiliated Hospital of Ningbo University宁波大学附属第一医院NingboHospital page
  8. Study siteFirst Hospital of China Medical University中国医科大学附属第一医院ShenyangHospital page
  9. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  10. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  11. Study siteFujian Medical University Union Hospital福建医科大学附属协和医院FuzhouHospital page
  12. Study siteGuangdong Provincial People's Hospital广东省人民医院GuangzhouHospital page
  13. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  14. Study siteHenan Provincial People's Hospital河南省人民医院ZhengzhouHospital page
  15. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  16. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  17. Study siteNanjing Drum Tower Hospital南京鼓楼医院NanjingHospital page
  18. Study sitePeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page
  19. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  20. Study siteSecond Affiliated Hospital of Xi'an Jiaotong University西安交通大学第二附属医院Xi'anHospital page
  21. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  22. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  23. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  24. Study siteShengjing Hospital of China Medical University中国医科大学附属盛京医院ShenyangHospital page
  25. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  26. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  27. Study siteThird Affiliated Hospital of Soochow University常州市第一人民医院ChangzhouHospital page
  28. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  29. Study siteUnion Hospital华中科技大学同济医学院附属协和医院WuhanHospital page
  30. Study siteWest China Hospital四川大学华西医院ChengduHospital page
  31. Study siteXijing Hospital空军军医大学西京医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06363994, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 60 years to Not stated; sex: all

    Registered eligibility fields

  2. ECOG PS score of 0 to 2.

    Inclusion criterion 5

  3. At least one measurable site of disease (the longest axis of the lymph node lesion is > 1.5 cm, or the longest diameter of the extranodal lesion is > 1.0 cm).

    Inclusion criterion 4

  4. Existing or prior history of other malignant tumor and no evidence of recurrence and metastasis within 2 years before screening.

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06363994, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Subjects ≥ 65 of age, or ≥ 60 and < 65 years old who are ineligible for stem cell transplant or have refused stem cell transplantation due to reason(s) including: Have not received prior systemic therapies for MCL.
  • Modified Ann Arbor stage II-IV. Patients with stage II require systemic treatment to be eligible, at the discretion of the investigator.
  • Histopathological confirmed MCL, expression of Cyclin D1 and/or t (11; 14) chromosomal translocation. Either fresh tissue or FFPE for diagnosis must be sent to central lab for final confirmation after randomization.
  • At least one measurable site of disease (the longest axis of the lymph node lesion is > 1.5 cm, or the longest diameter of the extranodal lesion is > 1.0 cm).
  • ECOG PS score of 0 to 2.

Exclusion Criteria:

  • Existing or prior history of other malignant tumor and no evidence of recurrence and metastasis within 2 years before screening.
  • Subjects with evident gastrointestinal dysfunction that may affect drug intake, transport or absorption, or subjects who have undergone total gastrectomy.
  • Subjects for whom the goal of therapy is tumor debulking prior to stem cell transplant.
  • Use of strong inhibitors or strong inducers of cytochrome P450 3A within 14 days or 5 half-lives, whichever is longer, before the first dose of study treatment; or plan to use strong inhibitors or strong inducers of CYP3A during the study.
  • Known central nervous system lymphoma.

Quoted from ClinicalTrials.gov, NCT06363994, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06363994, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06363994